Phase 3 Clinical Trials With Primary Completion Dates in September 2017
This is a list of Phase 3 trials with primary completion dates in September 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | 2017-09-01 | Phase 3 | NCT02746068 | A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions |
| AXSM | Axsome Therapeutics, Inc. | 2017-09-01 | Phase 3 | NCT02741791 | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder |
| CHRS | Coherus BioSciences, Inc. | 2017-09-01 | Phase 3 | NCT02486939 | A Long Term Safety Extension Study (CHS-0214-05) |
| CYTK | Cytokinetics, Incorporated | 2017-09-01 | Phase 3 | NCT02496767 | Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year |
| DBVT | DBV Technologies S.A. | 2017-09-01 | Phase 3 | NCT02916446 | Safety Study of Viaskin Peanut to Treat Peanut Allergy |
| ENDP | Endo International plc | 2017-09-01 | Phase 3 | NCT01210352 | Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects |
| GRFS | Grifols, S.A. | 2017-09-01 | Phase 3 | NCT02413580 | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations |
| MESO | Mesoblast Limited | 2017-09-01 | Phase 3 | NCT02652130 | Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD |
| MNK | Mallinckrodt plc | 2017-09-01 | Phase 3 | NCT01709747 | Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration |
| MNK | Mallinckrodt plc | 2017-09-01 | Phase 3 | NCT01709721 | Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration Using a Programmable Implantable Pump |
| NVIV | InVivo Therapeutics Holdings Corp. | 2017-09-01 | Phase 3 | NCT02138110 | The INSPIRE Study: Probable Benefit of the Neuro- Spinal Scaffold for Treatment of AIS A Thoracic Acute Spinal Cord Injury |
| RDHL | Redhill Biopharma Ltd. | 2017-09-01 | Phase 3 | NCT01951326 | Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease |
| TSRO | TESARO, Inc. | 2017-09-01 | Phase 3 | NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients |